Quick Answer
AYTU BIOPHARMA, INC reported R&D Expense of $1.33 million for fiscal year 2025.
AYTU BIOPHARMA, INC R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $1.33M | -52.1% |
| 2024 | $2.77M | -32.4% |
| 2023 | $4.09M | -67.7% |
| 2022 | $12.66M | +125.2% |
| 2021 | $5.62M | +226.5% |
| 2020 | $1.72M | +192.3% |
| 2019 | $589.1K | +251.5% |
| 2018 | $167.6K | -82.5% |
| 2017 | $959.9K | -84.3% |
| 2016 | $6.13M | +90.3% |
| 2015 | $3.22M | -18.2% |
| 2014 | $3.93M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| December 31, 2025 | $0.00 | -100.0% | — |
| September 30, 2025 | $0.00 | -100.0% | -100.0% |
| March 31, 2025 | $162.0K | -73.5% | -69.0% |
| December 31, 2024 | $522.0K | +0.2% | +22.5% |
| September 30, 2024 | $426.0K | -28.4% | -30.3% |
| March 31, 2024 | $611.0K | -28.6% | +17.3% |
| December 31, 2023 | $521.0K | -69.5% | -12.4% |
| September 30, 2023 | $595.0K | -44.1% | -30.5% |
- AYTU BIOPHARMA, INC showed a decrease of -52.1% in R&D Expense compared to the prior fiscal year.
- Over the 2014–2025 period, AYTU BIOPHARMA, INC’s r&d expense has declined by 66.3% (from $3.93 million to $1.33 million).
- The most recent figure is from AYTU BIOPHARMA, INC’s fiscal year 2025 report (Form 10-K), filed with the SEC on September 23, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: